MBI assessed as supplementary screening tool for women with dense breasts.
Molecular breast imaging (MBI) is effective as a supplementary screening tool to mammography for women with dense breasts, according to a study published in the American Journal of Roentgenology.
Researchers from Ohio, California, and New Hampshire performed a retrospective study to assess the utility of MBI as a supplementary screening tool for 1,696 women with dense breast tissue. They sought to determine cancer detection rates, recall rates, biopsy rates, and positive predictive values (PPVs).
The results showed that 13 mammographically occult malignancies were detected among the study group. Eleven were invasive, one was node positive, and one had unknown node positivity. Other findings showed:
• Lesion size ranged from 0.6 to 2.4 cm, mean 1.1 cm[[{"type":"media","view_mode":"media_crop","fid":"50915","attributes":{"alt":"©RSNA 2015.","class":"media-image media-image-right","id":"media_crop_9213433233653","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"6242","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 151px; width: 170px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©RSNA 2015.","typeof":"foaf:Image"}}]]
• Incremental cancer detection rate was 7.7%
• Recall rate was 8.4%
• Biopsy rate was 3.7%
• PPV for recall (PPV 1) was 9.1%
• PPV for biopsy (PPV 3) was 19.4%
While MBI does expose women to a higher radiation dose than does standard mammography, the effective dose from the MBI exam was 2.3 mSv, compared with a typical mammography dose of 0.56 mSv. “When incorporated into a community-based clinical practice environment, molecular breast imaging yielded a high incremental cancer detection rate of 7.7 percent at an acceptable radiation dose,” the researchers concluded.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography Study: AI Improves Breast Cancer Detection and Reduces Reading Time with DBT
April 3rd 2024An emerging artificial intelligence (AI) model demonstrated more than 12 percent higher specificity and reduced image reading time by nearly six seconds in comparison to unassisted radiologist interpretation of digital breast tomosynthesis (DBT) images.